NASDAQ · KALV
KalVista Pharmaceuticals, Inc.
$27.00$0.00 (0.0%)
KalVista Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
Loading market information…
NASDAQ · NAGE · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Niagen Bioscience Inc’s quoted price sits in the lower half of its reported 52-week range, 68.55% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Niagen Bioscience Inc’s next earnings report is currently expected on Nov 4, 2026, with estimated earnings per share of -$0.01. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Niagen Bioscience Inc’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and authorized healthcare practitioners resellers. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 12:27 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 7, 2025 | $0.04+100.0% vs estimate | $30.48M+12.58% vs estimate |
|---|
| Q4 2024 | Mar 4, 2025 | $0.09+300.0% vs estimate | $29.13M+8.78% vs estimate |
|---|
| Q3 2024 | Oct 31, 2024 | $0.03+413.96% vs estimate | $25.58M+6.44% vs estimate |
|---|
THE ANALYST VIEW
5 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 3 contributors · Median target $10.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$27.00$0.00 (0.0%)
KalVista Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$14.00$0.00 (0.0%)
Ventyx Biosciences, Inc.’s quoted price sits in the upper half of its reported 52-week range, 44.0% below the high.
$51.45+$0.71 (+1.4%)
Rigel Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.51% below the high.
$10.23-$0.29 (-2.76%)
Corvus Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.04% below the high.
$7.33-$0.16 (-2.14%)
Olema Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 79.78% below the high.
$10.36+$0.05 (+0.48%)
Zevra Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 31.12% below the high.
$7.41+$0.17 (+2.35%)
REGENXBIO Inc.’s quoted price sits in the lower half of its reported 52-week range, 54.23% below the high.
$8.88-$0.22 (-2.42%)
Prothena Corporation plc’s quoted price sits in the lower half of its reported 52-week range, 24.75% below the high.
